Viatris Inc (VTRS) Stock Price, Quote & News

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 724 514 1800

Website: www.viatris.com

Address:

Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States

HarveyToronto Apr. 23 at 7:28 PM

Wondering what drove the upward trend for Viatris ($VTRS) in 2025 and now in 2026? Beyond major debt paydowns and share buybacks, here is the real catalyst: Viatris is making a strategic play for the semaglutide (Ozempic/Wegovy) market, the most lucrative segment of the GLP-1 space. The key? In Oct 2024, Mylan (now part of Viatris) reached a crucial patent settlement with Novo Nordisk. While exact launch dates remain confidential, it secures $VTRS a definitive runway to launch generic semaglutide the moment the exclusivity window opens

0 · Reply

CoulterB Apr. 20 at 3:05 PM

$VTRS 20s after earning report.

0 · Reply

CoulterB Apr. 17 at 5:58 PM

$VTRS very bullish trend.

0 · Reply

ShirleyG Apr. 17 at 1:17 AM

$VTRS let's goooo 🔥🔥🔥🔥

0 · Reply

HarveyToronto Apr. 16 at 9:16 PM

$VTRS I see this one at 19.

0 · Reply

scotttrader213 Apr. 16 at 2:17 AM

$VTRS $TEVA for years $TEVA didn’t move. $VTRS is reminding me of $TEVA and now look at $TEVA. $VTRS long

0 · Reply

ShirleyG Apr. 16 at 1:51 AM

$VTRS ⏫️⏫️⏫️⏫️⏫️⏫️⏫️⏫️

0 · Reply

ItsCarRamRod Apr. 14 at 12:30 PM

$VTRS still looking bullish as it settled back into the uptrend channel.

0 · Reply

CapitalMonk Apr. 6 at 10:43 AM

$VTRS Price: $13.44 (-1.39%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.85% RSI: 48.6 | Momentum: Moderate Volume: -40.6% vs avg Volatility: 1.72% Support: $12.87 | Resistance: $14.52 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

ShirleyG Mar. 29 at 3:57 AM

$VTRS ⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️

0 · Reply

Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

$Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting$

Apr 10, 2026, 6:59 AM EDT - 17 days ago

Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Mar 31, 2026, 7:51 AM EDT - 27 days ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

CVS UNH

Mar 23, 2026, 6:59 AM EDT - 5 weeks ago

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

Mar 19, 2026, 10:00 AM EDT - 5 weeks ago

Viatris Transcript: Investor update

Mar 19, 2026, 8:30 AM EDT - 5 weeks ago

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

Mar 12, 2026, 11:11 AM EDT - 6 weeks ago

Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research

Mar 3, 2026, 10:41 AM EST - 7 weeks ago

These S&P 500 stocks are falling the hardest on Tuesday

ALB APO ARES BX CIEN FCX GEV

Feb 27, 2026, 1:03 PM EST - 2 months ago

AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.

DASH DPZ SJM

Feb 26, 2026, 8:37 AM EST - 2 months ago

Viatris forecasts 2026 profit below estimates on India manufacturing woes

Feb 26, 2026, 8:30 AM EST - 2 months ago

Viatris Earnings Call Transcript: Q4 2025

Feb 26, 2026, 6:59 AM EST - 2 months ago

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

Feb 26, 2026, 6:55 AM EST - 2 months ago

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

Feb 25, 2026, 6:59 AM EST - 2 months ago

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

Feb 19, 2026, 9:02 AM EST - 2 months ago

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

Feb 3, 2026, 4:34 PM EST - 2 months ago

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

Feb 3, 2026, 8:30 AM EST - 2 months ago

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Jan 20, 2026, 6:59 AM EST - 3 months ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

LXRX

Jan 13, 2026, 12:00 PM EST - 3 months ago

Viatris Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 9:05 AM EST - 3 months ago

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Jan 6, 2026, 9:00 AM EST - 3 months ago

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Dec 18, 2025, 6:59 AM EST - 4 months ago

Viatris Provides Pipeline Update on Four Regulatory Milestones

Dec 17, 2025, 6:59 AM EST - 4 months ago

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 6, 2025, 9:00 AM EST - 5 months ago

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Dec 3, 2025, 8:45 AM EST - 5 months ago

Viatris Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:30 AM EST - 5 months ago

Viatris Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 5 months ago

Viatris to Participate in Upcoming Investor Conferences

Nov 18, 2025, 6:30 AM EST - 5 months ago

Viatris Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 8:00 AM EST - 5 months ago

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

Nov 11, 2025, 8:45 AM EST - 5 months ago

Viatris Transcript: UBS Global Healthcare Conference 2025

Nov 6, 2025, 8:30 AM EST - 6 months ago

Viatris Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:16 AM EST - 6 months ago

Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Nov 6, 2025, 6:59 AM EST - 6 months ago

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Nov 4, 2025, 6:59 AM EST - 6 months ago

Viatris Announces Quarterly Dividend

Oct 15, 2025, 4:30 PM EDT - 6 months ago

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Oct 8, 2025, 11:00 AM EDT - 7 months ago

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Oct 1, 2025, 9:00 AM EDT - 7 months ago

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Aug 19, 2025, 9:00 AM EDT - 8 months ago

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Aug 11, 2025, 9:29 AM EDT - 9 months ago

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Aug 7, 2025, 9:36 AM EDT - 9 months ago

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Aug 7, 2025, 8:30 AM EDT - 9 months ago

Viatris Earnings Call Transcript: Q2 2025

Aug 7, 2025, 6:59 AM EDT - 9 months ago

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Aug 5, 2025, 6:55 AM EDT - 9 months ago

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Aug 1, 2025, 10:00 AM EDT - 9 months ago

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Jul 22, 2025, 11:19 AM EDT - 9 months ago

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

CIVI CMCSA CRGY CWEN KSS LNC NXST

Jul 18, 2025, 2:17 PM EDT - 10 months ago

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Jul 18, 2025, 8:47 AM EDT - 10 months ago

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Jul 18, 2025, 7:07 AM EDT - 10 months ago

Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 6:59 AM EDT - 10 months ago

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Jun 26, 2025, 6:55 AM EDT - 10 months ago

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Jun 12, 2025, 4:30 PM EDT - 11 months ago

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 10:40 AM EDT - 11 months ago

Viatris Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 8:45 AM EDT - 11 months ago

Viatris Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 1:12 PM EDT - 11 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

$Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions$

Jun 2, 2025, 8:00 AM EDT - 11 months ago

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

May 13, 2025, 8:01 PM EDT - 1 year ago

Viatris Transcript: BofA Securities 2025 Healthcare Conference

May 8, 2025, 8:30 AM EDT - 1 year ago

Viatris Earnings Call Transcript: Q1 2025

Mar 11, 2025, 2:00 PM EDT - 1 year ago

Viatris Transcript: Barclays 27th Annual Global Healthcare Conference

Feb 27, 2025, 8:30 AM EST - 1 year ago

Viatris Earnings Call Transcript: Q4 2024

Jan 14, 2025, 11:15 AM EST - 1 year ago

Viatris Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Nov 21, 2024, 5:30 AM EST - 1 year ago

Viatris Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 11:45 AM EST - 1 year ago

Viatris Transcript: UBS Global Healthcare Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Viatris Earnings Call Transcript: Q3 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Viatris Earnings Call Transcript: Q2 2024

Jun 11, 2024, 9:20 AM EDT - 2 years ago

Viatris Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 8:00 AM EDT - 2 years ago

Viatris Transcript: Jefferies 2024 Global Healthcare Conference

May 14, 2024, 1:00 PM EDT - 2 years ago

Viatris Transcript: BofA Securities 2024 Health Care Conference

May 9, 2024, 8:30 AM EDT - 2 years ago

Viatris Earnings Call Transcript: Q1 2024

Mar 27, 2024, 10:00 AM EDT - 2 years ago

Viatris Transcript: R&D Day 2024

Feb 28, 2024, 8:30 AM EST - 2 years ago

Viatris Earnings Call Transcript: Q4 2023

Jan 10, 2024, 1:30 PM EST - 2 years ago

Viatris Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Nov 15, 2023, 4:30 AM EST - 2 years ago

Viatris Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Viatris Earnings Call Transcript: Q3 2023

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Viatris Earnings Call Transcript: Q2 2023

Jun 13, 2023, 4:20 PM EDT - 3 years ago

Viatris Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

May 8, 2023, 8:30 AM EDT - 3 years ago

Viatris Earnings Call Transcript: Q1 2023

Feb 27, 2023, 8:30 AM EST - 3 years ago

Viatris Earnings Call Transcript: Q4 2022

Jan 10, 2023, 6:00 PM EST - 3 years ago

Viatris Transcript: JPMorgan Healthcare Conference

Nov 7, 2022, 8:30 AM EST - 3 years ago

Viatris Earnings Call Transcript: Q3 2022

Aug 8, 2022, 5:27 AM EDT - 4 years ago

Viatris Earnings Call Transcript: Q2 2022

May 9, 2022, 4:42 AM EDT - 4 years ago

Viatris Earnings Call Transcript: Q1 2022

Feb 28, 2022, 4:32 AM EST - 4 years ago

Viatris Earnings Call Transcript: Q4 2021

Nov 7, 2021, 7:00 PM EST - 4 years ago

Viatris Earnings Call Transcript: Q3 2021

Aug 9, 2021, 10:32 AM EDT - 5 years ago

Viatris Earnings Call Transcript: Q2 2021

May 10, 2021, 8:18 AM EDT - 5 years ago

Viatris Earnings Call Transcript: Q1 2021

Mar 1, 2021, 8:30 AM EST - 5 years ago

Viatris Transcript: Investor Day 2021

Feb 22, 2021, 8:00 AM EST - 5 years ago

Viatris Transcript: Guidance

HarveyToronto Apr. 23 at 7:28 PM

0 · Reply

CoulterB Apr. 20 at 3:05 PM

$VTRS 20s after earning report.

0 · Reply

CoulterB Apr. 17 at 5:58 PM

$VTRS very bullish trend.

0 · Reply

ShirleyG Apr. 17 at 1:17 AM

$VTRS let's goooo 🔥🔥🔥🔥

0 · Reply

HarveyToronto Apr. 16 at 9:16 PM

$VTRS I see this one at 19.

0 · Reply

scotttrader213 Apr. 16 at 2:17 AM

$VTRS $TEVA for years $TEVA didn’t move. $VTRS is reminding me of $TEVA and now look at $TEVA. $VTRS long

0 · Reply

ShirleyG Apr. 16 at 1:51 AM

$VTRS ⏫️⏫️⏫️⏫️⏫️⏫️⏫️⏫️

0 · Reply

ItsCarRamRod Apr. 14 at 12:30 PM

$VTRS still looking bullish as it settled back into the uptrend channel.

0 · Reply

CapitalMonk Apr. 6 at 10:43 AM

0 · Reply

ShirleyG Mar. 29 at 3:57 AM

$VTRS ⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️

0 · Reply

erevnon Mar. 24 at 2:48 PM

Barclays maintains Viatris $VTRS at Overweight and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ItsCarRamRod Mar. 20 at 2:46 PM

$VTRS can come down to $12 and technically still be in the bullish path.

0 · Reply

ItsCarRamRod Mar. 19 at 1:55 PM

$VTRS $16 to $13 in less than 3 weeks. and still falling like a rock.

0 · Reply

RunnerSignals Mar. 13 at 8:41 PM

$DG $TGT $KO $CTVA $VTRS price action showed controlled pullbacks and higher lows as money rotated toward stable earnings exposure https://stocksrunner.com/news/2026-03-13-top-stock-upgrades-today-in-the-buzz

0 · Reply

ItsCarRamRod Mar. 13 at 8:15 PM

$VTRS hit the very top of the channel and bounced. will see where it goes from here but it should be due a small B wave bounce.

0 · Reply

ItsCarRamRod Mar. 12 at 1:54 PM

$VTRS almost at the last support line that I can find as still see a bullish path for VTRS.

0 · Reply

StockConsultant Mar. 10 at 1:27 PM

$VTRS Viatris stock watch, pulback to 14.14 support area

1 · Reply

DailyAnalysis Mar. 6 at 4:59 PM

Despite weak guidance, $VTRS is hitting extreme 1D oversold levels. RSI and CCI suggest a 4H relief rally. Use 30M to time the bounce following the India facility news and restructuring plan. @DailyAnalysis

0 · Reply

ItsCarRamRod Mar. 5 at 7:52 PM

$VTRS the last time VTRS was over $16 in 2022 it quickly dropped to around $10. I expect this drop to follow a very similar path.

1 · Reply

DailyAnalysis Mar. 5 at 7:51 PM

0 · Reply

DailyAnalysis Mar. 5 at 8:57 AM

0 · Reply

ItsCarRamRod Mar. 3 at 11:11 PM

$VTRS $15 disappeared just as quick as $16 did. I do not show any support down to $13.

2 · Reply

Market Cap	16.99B
Revenue (ttm)	14.30B
Net Income (ttm)	-3.51B
EPS (ttm)	N/A
PE Ratio	6.25
Forward PE	6.05
Profit Margin	-24.58%
Debt to Equity Ratio	1.12

Volume	6,991,411
Avg Vol	10,378,520
Day's Range	N/A - N/A
Shares Out	1.16B
Stochastic %K	60%
Beta	0.83
Analysts	Sell
Price Target	$15.78